20221027104337.jpg&width=320&height=100)
Research Alert
Newswise — An ongoing phase II study (KEYNOTE-495/KeyImPaCT) led by a Yale Cancer Center expert explored the effectiveness of pembrolizumab-based combinations in reducing non-small cell lung cancer (NSCLC) tumors. New interim findings show that pembrolizumab-based combination therapies reduce the size of target tumors, resulting in a higher response rate for patients with advanced NSCLC and improved survival outcomes. The results were published in Nature Medicine on July 10, 2023.
“We are excited to share these new findings, which show promising results for pembrolizumab-based treatment regimens for patients with advanced NSCLC,” said senior and corresponding author Roy Herbst, MD, PhD, deputy director of Yale Cancer Center and assistant dean for translational research at Yale School of Medicine.
The study’s approach enables tailored treatment strategies and highlights the importance of personalized medicine for patients with NSCLC. The research was funded by Merck Sharp & Dohme, LLC, a subsidiary of Merck.
MEDIA CONTACT
Register for reporter access to contact detailsRELEVANT EXPERTS
Roy Herbst
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Deputy Director, Yale Cancer Center; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Assistant Dean for Translational Research, Yale School of Medicine; Director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; Co-Principal Investigator and Community Outreach Co-Leader, Cancer Disparities Firewall Project
Yale Cancer Center/Smilow Cancer Hospital
RSS